Want to see BCRX full AI Analyst Report?
BCRX Stock Chart & Stats
$9.50
-$0.02(-0.25%)
At close: 4:00 PM EST
$9.50
-$0.02(-0.25%)
Day’s Range― - ―
52-Week Range$6.00 - $11.22
Previous CloseN/A
Volume537.69K
Average Volume (3M)5.55M
Market Cap
$2.36B
Enterprise Value$2.93K
Total Cash (Recent Filing)$239.25M
Total Debt (Recent Filing)$858.08M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Jul 30, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.73
Shares Outstanding254,162,660
10 Day Avg. Volume5,019,223
30 Day Avg. Volume5,553,229
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-13.74
Price to Sales (P/S)1.87
P/FCF Ratio5.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.89Price Target Upside130.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.55
Revenue Forecast (FY)$669.39M
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive operating and free cash flow materially improves funding flexibility, reduces reliance on equity or dilutive financings, and supports commercialization and late‑stage programs. Strong cash conversion also enables milestone payments and licensing execution over the next 2–6 months.
Commercial Execution (ORLADEYO)Consistent top‑line growth and healthy new‑patient prescription trends indicate a durable commercial franchise for ORLADEYO. Stable prescriber additions and one‑year retention (~60%) support predictable recurring sales and underpin non‑GAAP profitability and cash generation into 2026 and beyond.
Pipeline De‑risking & LicensingOut‑licensing European rights and milestone/royalty structure transfers commercialization risk, secures near‑term cash, and preserves upside while allowing BioCryst to focus U.S. resources on approval and launch. This externalization improves capital efficiency and strengthens near‑term liquidity.
Bears Say
Negative Shareholders' EquityA negative equity base constrains financial flexibility and increases refinancing and covenant risk despite recent debt reduction. It complicates leverage metrics and can limit access to non‑dilutive capital, raising the cost of future funding and weakening the balance sheet over the medium term.
Acquisition Charge, Dilution & LeverageThe large GAAP R&D charge reflects the Astria acquisition economics and was paired with significant share issuance and a $400M credit facility. While it supports strategic assets, it increases diluted share count and financial leverage, constraining EPS recovery and raising investor scrutiny over integration execution.
HAE Market CompetitionHeightened competition from new injectable therapies creates structural pressure on market share, pricing, and gross‑to‑net dynamics. Even with solid retention, expanded treatment choices can slow uptake, raise marketing intensity needs, and compress long‑run margins in the core HAE franchise.
BioCryst News
BCRX FAQ
What was BioCryst Pharmaceuticals’s price range in the past 12 months?
BioCryst Pharmaceuticals lowest stock price was $6.00 and its highest was $11.22 in the past 12 months.
What is BioCryst Pharmaceuticals’s market cap?
BioCryst Pharmaceuticals’s market cap is $2.36B.
When is BioCryst Pharmaceuticals’s upcoming earnings report date?
BioCryst Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 8 days.
How were BioCryst Pharmaceuticals’s earnings last quarter?
BioCryst Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$2.98 earnings per share for the quarter, missing the consensus estimate of $0.044 by -$3.024.
Is BioCryst Pharmaceuticals overvalued?
According to Wall Street analysts BioCryst Pharmaceuticals’s price is currently Undervalued.
Does BioCryst Pharmaceuticals pay dividends?
BioCryst Pharmaceuticals does not currently pay dividends.
What is BioCryst Pharmaceuticals’s EPS estimate?
BioCryst Pharmaceuticals’s EPS estimate is 0.15.
How many shares outstanding does BioCryst Pharmaceuticals have?
BioCryst Pharmaceuticals has 254,162,660 shares outstanding.
What happened to BioCryst Pharmaceuticals’s price movement after its last earnings report?
BioCryst Pharmaceuticals reported an EPS of -$2.98 in its last earnings report, missing expectations of $0.044. Following the earnings report the stock price went down -2.215%.
Which hedge fund is a major shareholder of BioCryst Pharmaceuticals?
Currently, no hedge funds are holding shares in BCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.89 (130.41% Upside)
$21.89 (130.41% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $100.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.12%
Trailing 12-Months
Company Description
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
BCRX Stock 12 Month Forecast
Average Price Target
$21.89
▲(130.41% Upside)
Technical Analysis
Ownership Overview
1.48% Insiders
15.47% Mutual Funds
0.54% Other Institutional Investors
63.07% Public Companies and Individual Investors